ArticleFrontiers in oncology2025
Identification of key genes associated with perineural invasion in stage II colorectal cancer and their prognostic implications.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify key genes associated with perineural invasion (PNI) in stage II colorectal cancer (CRC) and develop a prognostic nomogram. The goal was to create a model for more precise prognosis assessment and to guide personalized treatment for stage II CRC patients with PNI. Methods: Bioinformatic analysis of The Cancer Genome Atlas (TCGA) database was used to identify differentially expressed genes (DEGs) associated with PNI in stage II CRC. Kaplan-Meier and Cox regression analyses identified prognostic genes for overall survival (OS). These genes, along with clinical factors, were integrated into a nomogram. The model's performance was evaluated using calibration curves, receiver operating characteristic (ROC)/area under the curve (AUC) analysis, and decision curve analysis (DCA). Key gene expression in CRC tissues was validated by immunohistochemistry (IHC) and correlated with clinicopathological parameters. Results: We identified 33 DEGs associated with stage II CRC and PNI. High expression of CLDN18 and FTCD were independent poor prognostic indicators. A nomogram incorporating these genes and clinical factors accurately predicted 1-, 3-, and 5-year overall survival (OS), with AUC values exceeding 0.7. Calibration curves and DCA confirmed the model's clinical utility. Immunohistochemistry (IHC) revealed that Claudin 18 protein expression was significantly higher in PNI-positive CRC tissues (P < 0.05) and correlated with age and lymphatic invasion (P < 0.05). Conclusion: We developed a novel prognostic nomogram for stage II CRC patients with PNI. This model provides a new tool for CRC prognosis, deepens the understanding of PNI pathogenesis, and helps identify therapeutic targets like Claudin 18, whose expression was confirmed as a potential biomarker. This tool can enhance personalized treatment strategies for this high-risk patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.